Innovative solutions to
keep your project on course

Study Design and Conduct

Collection of relevant and high-quality Phase 1 clinical pharmacology study data requires both robust protocol design and experienced study oversight. Careful planning with the help of a clinical pharmacologist or pharmacokineticist is crucial to avoid missteps in your clinical studies.

Nuventra has extensive experience with the design, conduct, analysis, and interpretation of data from each type of Phase 1 clinical pharmacology study needed for an individual drug development program.

While we can conduct any Phase 1 study, our focus and expertise in clinical pharmacology is our differentiator. This is about much more than just conducting one study, it’s about an integrated approach to designing, conducting, analyzing, and interpreting Phase 1 studies within the context of your overall drug development program. As part of the study design phase, our senior consultants will conduct a review of your clinical pharmacology strategy to establish an understanding of existing data and how to maximize the impact of the next study on the overall plan.

Clinical Pharmacology Studies Supported:

Our Phase 1 Study Design and Conduct Services:

  • Clinical pharmacology strategy development/review
  • Study design and protocol development
  • Study startup activities
  • Data management (eCRF, randomization, database build, edit check, etc.)
  • Robust PK analysis and standalone PK Report
  • Biostatistics
  • Clinical study report (CSR)
  • Study management
  • Clinical monitoring
  • Medical monitoring
  • CDISC datasets
  • Documents that are eCTD-publishing ready
  • Post-study update, if necessary, to clinical pharmacology strategy

Explore Our Blog

Pediatric drug development

Challenges in Pediatric Drug Development and Clinical Trials

Recently, the FDA released an update to the nearly two-decades old harmonized guidelines on clinical investigations in pediatric patients (originally…

Read More
T cells around a cancer cell

CAR T Cells Part II: Hurdles to Development and Approval

In our previous blog post, we discussed the revolutionary immunotherapies known as chimeric antigen receptor T-cells (CAR T). The first…

Read More
Cancer T-cells

Key Hurdles in Immuno-Oncology

Immuno-oncology is an exciting but challenging subspecialty that falls underneath the umbrella of oncology research and development. Unlike more traditional…

Read More